NX-5948-301: A phase 1 study of a new treatment called NX-5948 in adults with relapsed or refractory B-cell lymphoma

A phase 1 trial testing a new treatment called NX-5948 in adults with relapsed or refractory B-cell lymphoma.

You can share the following ClinicalTrials.gov Identifier with your medical team so they can find out more about the trial: NCT05131022

Trial aim and background

The aim of this trial is to find the highest safe dose of NX-5948 and to test how well the highest safe dose works for people with different types of B-cell lymphoma that has not responded to previous treatment (refractory) or has come back (relapsed) after treatment. NX-5948 is a new type of BTK degrader.

This is a phase 1 (early phase) trial. Little is known about the safety and effectiveness of this treatment. You might not benefit from the treatment, but the trial will give important information about this new treatment, which could help other people in the future.

Who can enter

Adults with any of the following types of lymphoma who have not responded to previous treatment may be eligible for this trial:

  • Chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL)
  • Diffuse large B-cell lymphoma (DLBCL) (subgroups include Richter-transformed DLBCL
  • High-grade B-cell lymphomas (HGBCL) not otherwise specified
  • Follicular lymphoma (FL)
  • Mantle cell lymphoma (MCL)
  • Marginal zone lymphoma (MZL)
  • Waldenström’s macroglobulinaemia (WM)
  • Primary central nervous system lymphoma (PCNSL)

Locations

  • St. James Hospital, Leeds
  • Clatterbridge Cancer Centre NHS Foundation Trust, Wirral
  • St. Bartholomew's Hospital, London
  • Sarah Cannon Research Institute, London
  • The Christie NHS Foundation Trust, Manchester
  • Oxford University Hospitals NHS Foundation Trust, Oxford
  • University Hospitals Plymouth NHS Trust, Plymouth
  • University Hospital Southampton NHS Foundation Trust, Southampton
  • Royal Marsden NHS Foundation Trust, Sutton
  • The Beatson WOS Cancer Centre, Glasgow

Further information

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/ct2/show/study/NCT05131022 

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.